BTOG 2022 | The impact of selpercatinib in patients with RET fusion-positive NSCLC
Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, comments on the recent approval of selpercatinib, an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase, in the NHS for patients with RET fusion-positive non-small-cell lung cancer (NSCLC). The newly approved drug represents a promising second line therapy for the aforementioned group of patients and has demonstrated CNS activity, which is especially important for patients with brain metastases. Dr Greystoke additionally highlights the need for next generation sequencing (NGS) panels to effectively identify patients with RET fusion-positive lung cancer. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Greystoke reports consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and research funding from AstraZeneca. He is also the clinical Lead for Cancer North East England Hull and Yorkshire Genomic Laboratory Hub and a member of the National Test Directory Evaluation Working Group.
